MAP2K7 and renal carcinoma: Although ATP1A1 exerts oncogenic functions via the ERK5 pathway in colorectal cancer (58), it prolongs survival in renal carcinoma by suppressing Raf/MEK/ERK signaling (59), consistent with our in vitro findings, where ATP1A1 knockdown enhanced proliferation, migration, and invasion in renal cancer cells.